Gotta love the... huh?s ...in this article...I know article/link below (re: Cantech letter/ Loe) has been posted, but it brought two things to mind.... First, If AdCom participant not convinced by the data (concerned about "some" of the data's shortcomings), yet seeing overwhelming positive safety data and MCNA still "directionally" effective.... wouldn't the appropriate choice be to ABSTAIN from the vote??? If the participant believes the shortcoming(s) in the data mean there is not enough evidence/proof to warrant a YES vote, using the same logic, doesn't this also imply (logically) there is not enough proof to warrant/ BE SURE of a NO vote is justified (particularly in light of other findings shown)?? Of course forget "need" all together as not part of the question of benefit vs risk. An ABSTAIN still sends a message and discussion/feedback already noted/has taken place. --- Second, refers to Loe's new 1-yr price target in article per quote --- "In a research update to clients today, Loe downgraded Telesta Therapeutics from Speculative Buy to Hold and cut his one-year price target from $1.70 to $0.30". I would add a HUH?? to Loe's $.30 "1-YEAR TARGET unless a complete "cover your butt"...just like many at the AdCom. There was no mention in article AdCom "vote" and discussion/feedback IS ONLY "ADVICE" to the FDA. The FDA approval or not for MCNA is still FAR FROM OVER. IMHO https://www.cantechletter.com/2015/11/telesta-therapeutics-gets-price-target-slashed-at-euro-pacific/